Palatin Technologies - PTN Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTN shares.
View PTN analyst ratings or view top-rated stocks.

2 brokers have issued twelve-month target prices for Palatin Technologies' shares. Their PTN share price forecasts range from $2.00 to $5.00. On average, they predict the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 1,029.0% from the stock's current price.
View analysts price targets for PTN or view top-rated stocks among Wall Street analysts.

Palatin Technologies' stock was trading at $0.43 at the beginning of the year. Since then, PTN stock has decreased by 27.9% and is now trading at $0.31.
View the best growth stocks for 2022 here.

Palatin Technologies saw a increase in short interest in July. As of July 31st, there was short interest totaling 2,160,000 shares, an increase of 33.3% from the July 15th total of 1,620,000 shares. Based on an average daily volume of 695,400 shares, the short-interest ratio is presently 3.1 days. Currently, 1.1% of the shares of the stock are short sold.
View Palatin Technologies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 27th 2022.
View our PTN earnings forecast.

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) announced its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). The biopharmaceutical company had revenue of $0.16 million for the quarter. During the same period last year, the business earned ($0.02) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM).

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

Palatin Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.10%).
View institutional ownership trends.

Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PTN stock can currently be purchased for approximately $0.31.

Palatin Technologies (NYSEAMERICAN:PTN) has a market capitalization of $71.83 million and generates $120,000.00 in revenue each year. The biopharmaceutical company earns $-33,600,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The official website for the company is www.palatin.com. The biopharmaceutical company can be reached via phone at (609) 495-2200, via email at investors@palatin.com, or via fax at 609-495-2202.